Intuitive Surgical, Inc. (NASDAQ:ISRG) shares are trading +0.31% thus far today and have traded in the range of 908.25 – 914.76 during the current session. In order to take a look at where the stock might headed longer term, we can also look at different sets of data. Sell-side research firms currently have a consensus one year price target of $884.47 on the stock according to First Call. This number can often vary from the Zacks or FactSet mean targets. The sell-side analysts are projecting earnings per share of $5.95 for the next fiscal quarter. For the current year, analysts are predicting earnings of $23.64 per share according to First Call.
Stock Technicals in Focus
In looking at where the stock is trading on a technical level, the stock is trading +9.16% away from its 50 day moving average of $833.96. Based on the most recent available data, the equity is -0.48% off of its 52-week high of $914.76 and +49.07% away from its 52-week low which is $610.71. In taking a look at the company’s valuation, the firm’s price to earnings ratio stands at 45.89. This is a crucial indicator investors watch as higher ratios compared to peers, would suggest higher future earnings growth potential for the stock. The price to current year EPS estimates from research analysts currently stands at 38.51. In looking further ahead, potential investors should note that the company’s price to next year’s EPS estimates is 33.37.
Today, the stock opened at $913.44 and the last bid at the time of writing stood at $910.36. During the session thus far, the equity dipped down to $908.25 and touched $914.76 as the high point. Intuitive Surgical, Inc. has a market cap of 33.54B and has seen an average daily volume of 328747 over the past three months.
Research analysts covering Valeant Pharmaceuticals International, Inc. (NYSE:VRX) are projecting that the shares reach $N/A within the next 12-18 months. This is the consensus number derived from the N/A analyst reports taken into consideration. The most bullish, or aggressive analyst target pins the projected price at $N/A, while the most bearish, or conservative analyst sees the stock reaching $N/A.
Broker Rating Update on Valeant Pharmaceuticals International, Inc. (NYSE:VRX)
Zacks provides analysts with an Average Broker Rating (or ABR), basing it on sell-side recommendations. Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) currently have an ABR of N/A. This is based on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell. Moving to earnings estimates, for this current fiscal period, Wall Street analysts have projected that the company will post $N/A earnings per share. This is the current Zacks consensus EPS which was calculated at the time of writing. Analysts will likely revise their estimates leading in to the actual results date.
taking a look at the most recent period, which closed on N/A, Valeant Pharmaceuticals International, Inc. reported EPS of $N/A for a surprise factor of N/A%, calculated by being $N/A away from analyst projections.
Investors will be marking their calendars for N/A, when the company is planning to release their quarterly results.